From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Executive Summary
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
You may also be interested in...
With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too
With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms. Now the company is trying to innovate its business organization to make the most of what it has
Highlights Of The American Society Of Clinical Oncology, In Brief
Erbitux significantly prolongs survival in first-line NSCLC: The addition of Bristol-Myers Squibb/ImClone/Merck KGaA's Erbitux (cetuximab) to platinum-based chemotherapy significantly increased overall survival in first-line treatment of non-small cell lung cancer, the first targeted therapy to show a significant survival benefit in NSCLC patients across all histological subtypes. In the Phase III FLEX trial, presented at the June 1 ASCO plenary session, over 1,000 patients with stage IIIB or IV NSCLC were randomized to receive Erbitux plus chemotherapy or chemo alone. Median overall survival was 11.3 months for the Erbitux arm versus 10.1 months for chemotherapy alone. The sponsors are discussing with FDA their plans to use the data as the basis of a supplemental BLA filing, which they hope to submit at the end of this year. Erbitux is approved for treatment of metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-based regimens, and as a single agent for metastatic CRC in patients intolerant to irinotecan
AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
CHICAGO - With the positive results of Roche's AVADO study of Avastin in first-line metastatic breast cancer, Roche and Genentech have the value of having a placebo-controlled, double-blind confirmation of bevacizumab's use in that setting. But what the presentation of AVADO at the American Society of Clinical Oncology annual meeting really did was revive debate over the breast cancer approval and raise questions about proper use in that setting